Consider long-term investments in companies within the biotech, pharma, and deep tech sectors that commercialize government-funded research. These industries have historically generated immense value by leveraging a publicly funded innovation pipeline from universities and federal agencies. However, a significant risk is the potential for a future Trump administration to cut federal research funding by over a third, which could disrupt this ecosystem. Such cuts would directly threaten the innovation pipeline for agencies like the NIH and NSF, creating headwinds for companies reliant on them. Therefore, investors should closely monitor U.S. political developments and federal budget policies as a key risk factor for these sectors.

Investment Theme: Public-Private Research Partnerships

• The podcast highlights the immense value created by the partnership between U.S. government funding, university research, and the private sector. The host, Scott Galloway, calls the spillover from this research "arguably the greatest investment in history." • This model has been a primary driver of innovation and shareholder value in several key industries. • Specific sectors and technologies mentioned as beneficiaries of this public funding include: - Biotechnology & Pharmaceuticals (e.g., chemotherapy, diabetes drugs) - Defense (e.g., weapons) - Technology (e.g., LED panels, energy-efficient technology) • Major Risk Factor Identified: A potential Trump administration is cited as a significant risk to this ecosystem. - The host mentions a budget proposal for the 2026 fiscal year that would cut U.S. federal government funding for basic research by more than a third (34%), from $45 billion down to $30 billion. - This is described as a "sugar high now" approach that prioritizes short-term gains over crucial long-term investments, potentially destroying the U.S.'s global standing and cutting the pipeline of talent for the technical workforce. - Government agencies at risk of being "cut to the bone" include the NIH (National Institutes of Health), NSF (National Science Foundation), and USDA (U.S. Department of Agriculture).

Takeaways

• Long-Term Bullish Thesis: Investors should consider the long-term potential of companies in the biotech, pharma, defense, and deep tech sectors that commercialize foundational research originating from universities. These companies often benefit from a publicly funded innovation pipeline. • Monitor Political Risk: The discussion presents a clear and present risk based on political outcomes. Investors in these sectors should pay close attention to U.S. federal budget negotiations and administration policies regarding science funding. • Potential for Volatility: The threat of significant funding cuts to agencies like the NIH and NSF could create headwinds and stock price volatility for companies reliant on this ecosystem for research and talent. • Actionable Insight: When evaluating companies in research-intensive fields, consider their exposure to federal research grants as a potential risk factor. A change in government policy could directly impact their long-term innovation capabilities and growth prospects.